Last reviewed · How we verify
Egg cell-derived Influenza Vaccine
Egg cell-derived Influenza Vaccine works by stimulating the body's immune system to produce antibodies against the influenza virus.
Egg cell-derived Influenza Vaccine works by stimulating the body's immune system to produce antibodies against the influenza virus. Used for Influenza prevention.
At a glance
| Generic name | Egg cell-derived Influenza Vaccine |
|---|---|
| Sponsor | Alachua Government Services, Inc. |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
This vaccine contains inactivated influenza virus antigens derived from egg cells, which are used to stimulate the body's immune system to produce antibodies against the influenza virus. These antibodies help to protect against future infections by recognizing and neutralizing the virus.
Approved indications
- Influenza prevention
Common side effects
- Pain, redness, or swelling at the injection site
Key clinical trials
- Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older (PHASE3)
- The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older (PHASE3)
- Efficacy Study of Two Influenza Vaccines and Placebo in Healthy Adult Subjects (PHASE3)
- Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults (PHASE2)
- Efficacy of Different Doses of Influenza Vaccine in Chronic Hemodialysis Patients (PHASE4)
- Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults (PHASE3)
- Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age (PHASE3)
- Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: